Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NMBR | P28336 | 2/20 | 0.42 |
| ▸ | TACR1 | P25103 | 2/20 | 0.42 |
| ▸ | CCKBR | P32239 | 3/20 | 0.42 |
| ▸ | CCKAR | P32238 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8242447 | 0.88 | MDM4 (0.43) | — | |
| SCHEMBL8241809 | 0.86 | CTSL (0.46) | MAPTSMN1; SMN2CTSLCTSSCTSK | |
| SCHEMBL8236150 | 0.84 | CCKBR (0.48) | MAPTSMN1; SMN2CTSLCTSSCTSK | |
| SCHEMBL15893676 | 0.84 | TLR2 (0.45) | MAPT | |
| SCHEMBL13049087 | 0.80 | TLR2 (0.47) | MAPT | |
| SCHEMBL17751704 | 0.79 | MDM4 (0.43) | — | |
| SCHEMBL12621110 | 0.79 | MDM4 (0.45) | — | |
| SCHEMBL16574818 | 0.78 | MDM4 (0.45) | — | |
| SCHEMBL4890850 | 0.78 | TACR1 (0.53) | CTSLCTSSCTSKTACR1CCKBR | |
| SCHEMBL4890847 | 0.78 | TACR1 (0.53) | CTSLCTSSCTSKTACR1CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119395-A1 | Novel Depsipeptides and Process for Preparing Same | CUBIST PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20060194714-A1 | Novel depsipeptides and process for preparing same | CUBIST PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194714-A1 | Novel depsipeptides and process for preparing same | VIP, DNPEP, PREP | MAPT 2106/4885SMN1; SMN2 3788/4885CTSL 124/4885 |
| US-20080119395-A1 | Novel Depsipeptides and Process for Preparing Same | VIP, DNPEP, PREP | MAPT 2106/4885SMN1; SMN2 3788/4885CTSL 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.